DE69426564T2 - Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28 - Google Patents

Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28

Info

Publication number
DE69426564T2
DE69426564T2 DE69426564T DE69426564T DE69426564T2 DE 69426564 T2 DE69426564 T2 DE 69426564T2 DE 69426564 T DE69426564 T DE 69426564T DE 69426564 T DE69426564 T DE 69426564T DE 69426564 T2 DE69426564 T2 DE 69426564T2
Authority
DE
Germany
Prior art keywords
production
transgenic mice
missing expression
expression
missing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69426564T
Other languages
English (en)
Other versions
DE69426564D1 (de
Inventor
Craig Bernie Thompson
Tak Wah Mak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ontario Cancer Institute
University of Michigan
Original Assignee
Ontario Cancer Institute
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontario Cancer Institute, University of Michigan filed Critical Ontario Cancer Institute
Publication of DE69426564D1 publication Critical patent/DE69426564D1/de
Application granted granted Critical
Publication of DE69426564T2 publication Critical patent/DE69426564T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70589CD45
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • A01K2267/0325Animal model for autoimmune diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0381Animal model for diseases of the hematopoietic system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Packaging For Recording Disks (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69426564T 1993-05-26 1994-05-25 Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28 Expired - Fee Related DE69426564T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6776793A 1993-05-26 1993-05-26
PCT/US1994/005913 WO1994028123A1 (en) 1993-05-26 1994-05-25 Mammals lacking expression of cd28 transgenic

Publications (2)

Publication Number Publication Date
DE69426564D1 DE69426564D1 (de) 2001-02-15
DE69426564T2 true DE69426564T2 (de) 2001-05-31

Family

ID=22078279

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426564T Expired - Fee Related DE69426564T2 (de) 1993-05-26 1994-05-25 Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28

Country Status (9)

Country Link
US (3) US6664107B1 (de)
EP (1) EP0701607B1 (de)
AT (1) ATE198621T1 (de)
AU (1) AU685811B2 (de)
DE (1) DE69426564T2 (de)
ES (1) ES2155474T3 (de)
GR (1) GR3035603T3 (de)
PT (1) PT701607E (de)
WO (1) WO1994028123A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264915B1 (en) 1992-09-13 2001-07-24 The President And Fellows Of Harvard College Process for detecting potential carcinogens
US6025183A (en) * 1994-02-28 2000-02-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transgenic animal assay system for anti-cholinesterase substances
WO1995034640A1 (en) * 1994-06-13 1995-12-21 Henry Ford Health System A novel neuronal-neonatal gene: neuronatin
HUP9801629A3 (en) * 1995-02-09 2000-10-30 Icn Pharmaceuticals Inc Costa Methods and compositions for regulation of cd28 expression
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5858661A (en) 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US20060021070A1 (en) * 1996-04-01 2006-01-26 University of Massachusetts, a Public Institution of Higher Education of the Commonwealth of MA Production of chimeric bovine or porcine animals using cultured inner cell mass
US7223849B1 (en) 1996-07-01 2007-05-29 Genesense Technologies Inc. Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5919656A (en) * 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
AU4964097A (en) * 1996-11-15 1998-06-10 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin genes (i)
US7071171B1 (en) 1996-12-20 2006-07-04 Board Of Regents The University Of Texas System Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US5817912A (en) * 1997-01-16 1998-10-06 B.M.R.A. Corporation B.V. Transgenic mice with disrupted NPY Y1 receptor genes
AU9110798A (en) 1997-08-21 1999-03-08 Quark Biotech, Inc. Hypoxia-regulated genes
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
WO1999035279A1 (en) 1998-01-12 1999-07-15 Georgetown University Medical Center G protein-related kinase mutants in essential hypertension
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6492138B1 (en) * 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
ATE377077T1 (de) 1999-04-28 2007-11-15 Genetics Inst Llc Humane gil-19/ae289 proteine und dafür kodierende polynukleotide
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US7638324B2 (en) 2000-04-06 2009-12-29 Burnham Institute For Medical Research Bcl-G polypeptides, encoding nucleic acids and methods of use
US20040034192A1 (en) * 2000-01-06 2004-02-19 Seishi Kato Human proteins having hyprophobic domains and dnas encoding these proteins
WO2001053323A2 (en) 2000-01-24 2001-07-26 Ramot University Authority For Applied Research & Industrial Development Ltd. Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
EP1276500B1 (de) 2000-03-13 2011-06-08 Cornell Research Foundation, Inc. Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US6686180B2 (en) * 2000-04-04 2004-02-03 Baxter International Inc. Method for the production of bacterial toxins
US7045314B2 (en) * 2000-04-04 2006-05-16 Baxter International Inc. Method for the production of bacterial toxins
US6503712B1 (en) 2000-05-10 2003-01-07 Amgen Inc. Methods and compositions for preparing a genomic library for knockout targeting vectors
ES2317917T3 (es) 2000-06-28 2009-05-01 Amgen Inc. Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20050239125A1 (en) * 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
WO2003001876A2 (en) 2001-06-26 2003-01-09 Senomyx, Inc. T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
AU2002358921A1 (en) * 2001-07-10 2003-04-28 Omnio Ab Novel drug targets for arthritis
AU2002318229B2 (en) 2001-07-10 2008-03-13 Senomyx, Inc. Use of specific T2R taste receptors to identify compounds that block bitter taste
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
US7195916B2 (en) * 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
ATE439041T1 (de) * 2001-09-13 2009-08-15 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
AU2002358947A1 (en) 2001-12-05 2003-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
EP1329506A1 (de) * 2002-01-18 2003-07-23 Cypro S.A. Verfahren zur Quantifizierung vom RNA Niveau in vivo
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
AU2003217693A1 (en) * 2002-02-22 2003-09-09 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
CN103275058B (zh) 2003-08-06 2016-02-24 西诺米克斯公司 调味剂、味道调节剂、促味剂、味觉增强剂、鲜味剂或甜味剂和/或增强剂及其用途
US7415011B2 (en) * 2003-08-29 2008-08-19 Sun Microsystems, Inc. Distributed switch
EP1735435A1 (de) * 2004-03-18 2006-12-27 Fred Hutchinson Cancer Research Center Verfahren und zusammensetzungen unter beteiligung von s-ship-promotorbereichen
CA2579790A1 (en) * 2004-07-30 2006-02-09 Mount Sinai School Of Medicine Of New York University Npc1l1 and npc1l1 inhibitors and methods of use thereof
CN101437539B (zh) * 2005-07-05 2013-10-02 康奈尔研究基金会(有限公司) 通过干扰cd99l2阻断白细胞迁出和炎症
JP5342878B2 (ja) 2005-10-20 2013-11-13 セノミクス・インコーポレーテッド キメラヒト甘味‐旨味および旨味‐甘味味覚受容体
EP1984040A1 (de) 2006-01-31 2008-10-29 Multi Gene Vascular Systems, Inc. Arznei-eluierende intravaskuläre prothesen und verwendungsverfahren
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
EP3235811B1 (de) 2006-04-21 2018-07-25 Senomyx, Inc. Verfarhen zur herstellung von oxalamiden
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CA2664318C (en) 2006-09-14 2017-05-23 Andrew L. Pearlman Long lasting drug formulations
US7943590B2 (en) 2007-03-16 2011-05-17 Multi-Gene Vascular Systems Ltd. Compositions and methods for treating ophthalmic disorders
EP2514766A3 (de) 2007-03-29 2013-06-05 Technion Research & Development Foundation Ltd. Antikörper, Verfahren und Kits zur Diagnose und Behandlung von Melanomen
EP2195656A4 (de) 2007-08-21 2011-10-19 Senomyx Inc Menschliche t2r-bitterkeit-rezeptoren und verwendungen davon
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US8093043B2 (en) * 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2324044A4 (de) 2008-08-04 2012-04-25 Univ Miami Sting (stimulator von interferongenen) als regulator angeborener immunreaktionen
EA201990619A1 (ru) 2008-10-10 2019-07-31 Амген Инк. Fgf21 мутанты и их применение
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
US8188040B2 (en) 2009-05-05 2012-05-29 Amgen Inc. FGF21 mutants and uses thereof
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
AU2010326024A1 (en) * 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
EP2582396A4 (de) 2010-06-15 2014-01-01 Medgenics Medical Israel Ltd Heilmittelformulierungen mit langzeitwirkung
WO2013091130A1 (zh) * 2011-12-19 2013-06-27 中国农业大学 猪cd28受体,编码其的基因及其应用
WO2015059701A1 (en) 2013-10-24 2015-04-30 Medgenics Medical Israel Ltd. Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals

Also Published As

Publication number Publication date
DE69426564D1 (de) 2001-02-15
US5557032A (en) 1996-09-17
AU685811B2 (en) 1998-01-29
EP0701607A1 (de) 1996-03-20
US5616491A (en) 1997-04-01
WO1994028123A1 (en) 1994-12-08
GR3035603T3 (en) 2001-06-29
US6664107B1 (en) 2003-12-16
AU6918794A (en) 1994-12-20
ES2155474T3 (es) 2001-05-16
EP0701607B1 (de) 2001-01-10
PT701607E (pt) 2001-05-31
ATE198621T1 (de) 2001-01-15

Similar Documents

Publication Publication Date Title
DE69426564T2 (de) Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28
DE68915070T2 (de) Zellkultur-Reaktor.
IT8820474A0 (it) Turbopropulsore ad eliche propfan.
DE69133557D1 (de) Homologe rekombination in säugetier-zellen
DE3879894D1 (de) Waage mit mehreren lastzellen und ausgleich.
DE69232952D1 (de) Antikörper der Rezeptoren von pluripotenten hämatopoetischen Stammzellen flk-1
DE68915338T2 (de) Gitter-Koppler mit monolithisch integriertem Quantum-Well-Index-Modulator.
DE69218613D1 (de) Konzentrator-solarzelle mit multi-quantum-well system in der verarmungszone der zelle
DK483382A (da) Copolyesterbindefilamenter og -fibre
DE69334211D1 (de) Multidrug resistenz gen
FR2491479B1 (fr) Copolyester terephtalique et fibres obtenues
DE69021721D1 (de) Formteile zur verwendung bei der herstellung von glaswollerzeugnissen.
DE3863095D1 (de) Korrosionsbestaendige brennstoffzellenstruktur.
DE3852283D1 (de) Herstellung von Verbundwerkstoffen.
FI882334A0 (fi) Foerbaettrad polyetylenfibermassa.
ATE56755T1 (de) Stamm von clostridium acetobutylleum und verfahren zur herstellung desselben.
DE3872558T2 (de) Duennschichtreaktoren zur umsetzung von methan.
DE3873342T3 (de) Nicht-zylindrischer reaktor zur herstellung von furnace-russ.
DE3864512D1 (de) Verfahren zur herstellung von kandis mit gepressten gaszellen.
ES2089122T3 (es) Vectores de expresion de adn recombinante y compuestos de adn que codifican la actividad de la isopenicilina n epimerasa.
DE69103847T2 (de) Glutaraldehydharz-Verbindungssystem für Herstellung von Holzprodukten.
FI872943A (fi) Reaktor avsedd foer att alstra biogas.
DE3772282D1 (de) Substituierte aminoxysuccinate und deren verwendung als stabilisatoren.
DE3882900D1 (de) Substituierte veresterte hydroxylamine und deren verwendung als stabilisatoren.
DE3882220D1 (de) Herstellung von chlordioxyd in einer elektrolytischen zelle.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee